IN-STENT STENOSIS: PATHOLOGY AND IMPLICATIONS FOR THE DEVELOPMENT OF DRUG ELUTING STENTS
Top Cited Papers
Open Access
- 1 February 2003
- Vol. 89 (2), 218-224
- https://doi.org/10.1136/heart.89.2.218
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationNew England Journal of Medicine, 2002
- First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent RestenosisCirculation, 2002
- Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting StentsCirculation, 2001
- Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergyJournal of Clinical Investigation, 2001
- Effect of p27 Deficiency and Rapamycin on Intimal Hyperplasia: In Vivo and In Vitro Studies Using a p27 Knockout Mouse ModelLaboratory Investigation, 2001
- Neointimal Tissue Response at Sites of Coronary Stenting in HumansCirculation, 1998
- Rapamycin Resistance Tied to Defective Regulation of p27Kip1Molecular and Cellular Biology, 1996
- Arterial Remodeling After Coronary AngioplastyCirculation, 1996
- The restenosis paradigm revisited: An alternative proposal for cellular mechanismsJournal of the American College of Cardiology, 1992
- Restenosis 1 to 24 months after clinically successful coronary balloon angioplasty: A necropsy study of 20 patientsJournal of the American College of Cardiology, 1991